top of page
 divarasib: A KRAS G12C inhibitor being evaluated in clinical studies
 divarasib: A KRAS G12C inhibitor being evaluated in clinical studies

Wed, Nov 29

|

Webinar

divarasib: A KRAS G12C inhibitor being evaluated in clinical studies

Join us for an informational presentation provided by our partners at Roche / Genentech.

Registration is closed
See other events

Time & Location

Nov 29, 2023, 12:00 PM – 1:00 PM EST

Webinar

About the Event

On Wednesday, November 29th, KRAS KICKERS will host an informational presentation given by Roche/Genentech titiled, divarasib: A KRAS G12C inhibitor being evaluated in clinical studies. The presentation will begin at 9:00am PST / 12:00pm EST/ 6:00pm CET. A link to join this event will be included in a follow-up email for those who RSVP to the event. There will be an opportunity for Q&A. 

An event for this link will be shared once registration is completed here.

More About This Event

Objectives include:

  • An Introduction to KRAS G12C and divarasib

  • Presentation of clinical data from ongoing Phase 1 study of divarasib

Share This Event

Genentech_Logo.png_dark blue text that reads, "Genetech." Gray italicized text that reads, "a member of the Roche Group."
Blue capitalized text on a gray background. Text reads, "Amgen."
Dark blue text on top of sea foam text. Text reads, "Verastem Oncology."
Black capitalized text that reads, "Revolution Medicine."
bottom of page